Enhertu
Imported from official source
Enhertu Active substance Trastuzumab deruxtecan Holder Daiichi Sankyo Belgium N.V.-S.A Status Running Indication treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options Public documents Approbation Information for the patient Informed consent …
This version
- Version
- 1 of 1
- Recorded
- November 09, 2026 08:32
- Change
- Initial
- Content hash
a8d97ffe63bd7edac1ec24969ad17e36- All versions
- Revision history